{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006150","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2025-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.620490+00:00","generated_at":"2026-05-22T22:06:15.542902+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Bio-Path announces third pre-clinical milestone for BP1001-A in obesity/Type 2 diabetes","bullets":["BP1001-A rescues AKT activity decrease in liver cells, preventing insulin resistance.","Data confirm potential of BP1001-A to treat obesity in Type 2 diabetes patients.","Pre-clinical testing in HepG2 liver cell model supports earlier results in muscle cells.","Next step: mouse model study; IND filing expected in 2025 for Phase 1 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006150","json":"https://secwatch.observer/filing/0001558370-25-006150.json","markdown":"https://secwatch.observer/filing/0001558370-25-006150.md","text":"https://secwatch.observer/filing/0001558370-25-006150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837025006150/0001558370-25-006150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837025006150/bpth-20250501x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T22:06:15.542902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}